Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR4 | P22455 | 8/20 | 0.68 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.68 |
| ▸ | FGFR1 | P11362 | 7/20 | 0.58 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.58 |
| ▸ | BTK | Q06187 | 9/20 | 0.52 |
| ▸ | TEC | P42680 | 2/20 | 0.48 |
| ▸ | TXK | P42681 | 2/20 | 0.48 |
| ▸ | BMX | P51813 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27188377 | 1.00 | FGFR4 (0.68) | FGFR4FGFR2FGFR1FGFR3BTK | |
| SCHEMBL27188370 | 1.00 | FGFR4 (0.68) | FGFR4FGFR2FGFR1FGFR3BTK | |
| SCHEMBL27188456 | 0.91 | FGFR4 (0.71) | FGFR4FGFR2FGFR1FGFR3 | |
| SCHEMBL27188458 | 0.91 | FGFR4 (0.71) | FGFR4FGFR2FGFR1FGFR3 | |
| SCHEMBL27188437 | 0.88 | FGFR4 (0.86) | FGFR4FGFR2FGFR1FGFR3BTK | |
| SCHEMBL30101089 | 0.88 | FGFR4 (0.86) | FGFR4FGFR2FGFR1FGFR3BTK | |
| SCHEMBL27188441 | 0.88 | FGFR4 (0.86) | FGFR4FGFR2FGFR1FGFR3BTK | |
| SCHEMBL27188670 | 0.87 | FGFR1 (0.53) | FGFR4FGFR2FGFR1FGFR3 | |
| SCHEMBL27188671 | 0.87 | FGFR1 (0.53) | FGFR4FGFR2FGFR1FGFR3 | |
| SCHEMBL30515867 | 0.86 | FGFR4 (0.51) | FGFR4FGFR2FGFR1FGFR3BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115433190-A | Preparation method and application of irreversible heterocyclic compound FGFR inhibitor | 药雅科技(上海)有限公司 | 2022-12-06 | — | — | CN | disclosed |